Statens Serum Institut
Records under this name other than the patents Statens Serum Institut holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 21 patents it holds.
Back to Statens Serum Institut
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,753,875 | Compositions and means for diagnosing microbial infections Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,749,507 | Malaria vaccine Term ended Term ended May 8, 2026 · From the USPTO record | Term ended | Term ended May 8, 2026 | From the USPTO record |
| US 11,278,581 | Use of Vaginal Lactobacilli for Improving the Success Rate of in Vitro Fertilization Lapsed on the fee record Ended Mar 22, 2026 · High confidence | Lapsed on the fee record | Ended Mar 22, 2026 | High confidence |
| US 8,277,823 | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids Term ended Term ended Aug 21, 2025 · From the USPTO record | Term ended | Term ended Aug 21, 2025 | From the USPTO record |
| US 8,293,250 | Tuberculosis vaccines comprising antigens expressed during the latent infection phase Lapsed on the fee record Ended Oct 23, 2024 · From the USPTO record | Lapsed on the fee record | Ended Oct 23, 2024 | From the USPTO record |
| US 7,838,013 | Specific epitope based immunological diagnosis of tuberculosis Term ended Term ended Oct 3, 2024 · From the USPTO record | Term ended | Term ended Oct 3, 2024 | From the USPTO record |
| US 8,241,610 | Adjuvant combinations of liposomes and mycobacterial lipids for immunization compositions and vaccines Term ended Term ended Jul 7, 2024 · From the USPTO record | Term ended | Term ended Jul 7, 2024 | From the USPTO record |
| US 8,114,609 | ADAM12, a novel marker for abnormal cell function Lapsed on the fee record Ended Feb 14, 2024 · From the USPTO record | Lapsed on the fee record | Ended Feb 14, 2024 | From the USPTO record |
| US 8,101,193 | Tuberculosis vaccines comprising antigens expressed during the latent infection phase Lapsed on the fee record Ended Jan 24, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 24, 2024 | From the USPTO record |
| US 7,838,018 | Adjuvant combinations for immunization composition and vaccines Term ended Term ended Jan 4, 2024 · From the USPTO record | Term ended | Term ended Jan 4, 2024 | From the USPTO record |